Y
YGION Biomedical
Develops individualized neoantigen-based cancer vaccines for personalized cancer treatment
About YGION Biomedical
Based in Vienna, Austria, YGION Biomedical GmbH is a preclinical-stage biopharmaceutical company established in 2022. The firm was founded by a team of experienced biotech veterans and entrepreneurs with the objective of developing individualized immunotherapies for cancer treatment. The leadership team includes co-founders Dr. Wolfgang Fischl as Chief Executive Officer and Dr. Georg Casari as Chief Operating Officer.
YGION is focused on creating personalized "plug-and-play" cancer vaccines designed to activate a patient's own immune system to fight the disease. The company's business model revolves around the research and development of these bespoke therapies, with a strategy that involves securing funding to advance its programs through preclinical and clinical trials. A significant milestone was achieved in May 2024, when YGION secured €15 million ($16.1M) in a Series A financing round from an Austrian private trust. This capital is being used to further the development of its core technology and lead program.
The company's central product is its proprietary YGNITE™ technology platform, which is engineered to produce neoepitope peptide vaccines tailored to each patient's specific tumor. This platform integrates three core areas: advanced next-generation sequencing (NGS) for detailed analysis of tumor and healthy tissue; an in-house bioinformatics platform to identify and select key neoepitopes; and the proprietary CARGONAUT™ immune-modulating carrier system. The CARGONAUT™ system links to the synthesized neoepitopes and delivers them to the patient's antigen-presenting cells, inducing a precise and powerful tumor-specific immune response. YGION's lead program, YG-01, is currently in the preclinical development stage, with the recent funding aimed at moving it towards clinical validation.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | May 2024 | $17M | $66M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for YGION Biomedical is 980 monthly website visits, down 30% over the last three months. YGION Biomedical's team grew 23.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
YGION Biomedical in the Vienna ecosystem
The YGION Biomedical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about YGION Biomedical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See YGION Biomedical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









